Download Free Medical ARV Treatment Guidelines for a Public Health Approach - Product Selection for HIV Treatment PowerPoint Presentation

ARV Treatment Guidelines for a Public Health Approach - Product Selection for HIV Treatment PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : This medical presentation titled ""ARV Treatment Guidelines for a Public Health Approach - Product Selection for HIV Treatment "" is about therapeutic and clinical goals in HIV/AIDS treatment, treatment of HIV infections in various population groups, starting treatment, treatment of opportunistic infections (OI), and product selection.

Tags : ARV Treatment, Human Immunodeficiency Virus, HIV, infection, cells, immune system, AIDS, Acquired Immune Deficiency Syndrome, HIV Positive, Anti-HIV Drug, antiretroviral drugs, AIDS drugs, HIV Protease, Alternative Therapies, therapy, Non-Nucleoside Reverse Transcriptase Inhibitors, NNTRIs, Protease Inhibitors, PIs,

Published on : Apr 22, 2021 | Views : 2112 | Downloads : 5

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

1 ARV Treatment Guidelines for a Public Health Approach Product Selection for HIV Treatment Vincent Habiyambere January 2006
Slide 2-

desirable 2 Outline Unit 1 Treatment Therapeutic & clinical goals in HIV/AIDS treatment Treatment of HIV infections in various population groups when to start treatment ; WHO Clinical Staging for adults and adolescents Treatment of Opportunistic Infections (OI)
Slide 3-

desirable 3 Outline Unit 2 Product Selection Basic elements of the selection process Selection of ARVs based on treatment protocols Public health considerations of 1st line regimens Major problems of 2nd line regimens WHO recommended 1st & 2nd line regimens for adults and adolescents WHO recommended 1st & 2nd line regimens for children Simplified guidelines Dosages of ARVs for Adults and adolescents Non ARV essential commodities
Slide 4-

key 4 Unit 1 Treatment
Slide 5-

key 5 Global summary of the HIV and AIDS epidemic, December 2005 . Number of people living with HIV in 2005 Total 40.3 million Adults 38.0 million Women 17.5 million Children under 15 years 2.3 million People newly infected with HIV in 2005 Total 4.9 million Adults 4.2 million Children under 15 years 700 000 AIDS deaths in 2005 Total 3.1 million Adults 2.6 million Children under 15 years 570 000
Slide 6-

key 6 1.1 Goals in HIV/AIDS Treatment Reduction of HIV related morbidity and mortality Improved health status, quality of life with effects for the individual, the family and the society Restoration and preservation of immunology functions Maximal and durable suppression of viral replication Reduced need for medical intervention and support Prevention/reduction of drug resistant strains of HIV and OI’s Reduction and control of drug side effects and support for adherence
Slide 7-

key 7 Pre-Conditions for Treatment Adequate social support and patient care taker available Adequate food supplies Adequate health facilities nearby Appropriate education for the patient re: adherence and side effect issues Adequate testing and monitoring available
Slide 8-

relevant 8 Basic Components of HIV/AIDS Treatment Use of Antiretrovirals to prevent replication of the Human Immunodeficiency Virus (HIV) in cells Treatment of Opportunistic Infections caused by a weakened immune system Monitoring, evaluation and adjustment of treatment to prevent drug resistance; to maximize effects of ART and to minimize consequences of toxicity and side effects.
Slide 9-

key 9 1.2 Treatment of HIV Infections in Various Population Groups Adults and adolescents Pregnant women or women of child-bearing age Children People with TB & HIV Co-infection Health and emergency workers after occupational exposure Victims of sexual assault
Slide 10-

key 10 ARV Therapy: A Public Health Approach
Slide 11-

key 11 The new WHO ARV Guidelines Standardization of ARV therapy will allow for more rapid implementation: easier to train professionals easier to procure ARVs, reduce stock outs easier to evaluate effectiveness easier to monitor patients
Slide 12-

key 12 A public health approach to antiretroviral therapy Key technical questions: When should treatment be started? What treatments can be used? When and how should treatments be changed? How should treatments be monitored?
Slide 13-

key 13 1. When to Start ARV in Adults/Adolescents If CD4 testing available: WHO stage IV disease, regardless of CD4 counts WHO stage III disease, consider ART* using CD4 cell counts <350/mm3 to assist decision-making WHO stage I or II if CD4 cell counts
Slide 14-

relevant 14 WHO Clinical Stages for adults and adolescents WHO Clinical Stage I (Asymptomatic) HIV positive, no weight loss No symptoms or only generalized lymphadenopathy Able to do normal activities WHO Clinical Stage II (Mild disease) Mild weight loss (5-10%), minor disease symptoms: sores or cracks around lips, itching rash, H. Zoster, recurrent upper RI, sinusitis, recurrent mouth ulcers Still able to do normal activities
Slide 15-

relevant 15 WHO Clinical Stages for adults and adolescents (Cont'd) WHO Clinical Stage III (Moderate disease) Weight loss >10%, oral thrush (oral leukoplakia), over 1 month diarrhea or fever, pulmonary TB, severe bacterial infections (pneumonia, muscle infection), TB lymphadenopathy, acute necrotizing ulcerative gingivitis/periodontitis, other bacterial infections May be bedridden <50% per day over a one month period WHO Clinical Stage IV (Severe disease: AIDS) AIDS defining illnesses: wasting syndrome, oesophageal thrush, >1 month H. simplex ulcerations, lymphoma, Kaposi sarcoma, invasive cervical cancer, Pneumocystis pneumonia, CMV retinitis, extrapulmonary TB, toxoplasma brain abscess, cryptococcal meningitis, HIV encephalopathy, visceral leishmaniasis. Bedridden >50% /day over one month period
Slide 16-

key 16 Treatment of Opportunistic Infections (OI) Treat promptly in accordance with national protocols, even when ARV’s are not available National protocols for the management of OIs required Uninterrupted supply of Medicines for OIs required
Slide 17-

key 17 2. Product Selection; Which ARV to use?
Slide 18-

key 18 2.1 Basic Elements of the Selection Process Selection committee is multi-disciplinary representatives of AIDS council, national drug formulary committee, HIV specialists (doctors, nurses pharmacists, procurement specialists) & PLWHA Drug selection should be based on pre-determined criteria Fixed dose combination should be considered to optimize adherence Important to use INNs (int'l nonproprietary names instead of brand names)
Slide 19-

key 19 2.2 Selection of ARV’s Based on National Treatment Protocols First line ARV treatment Second line ARV treatment PMTCT Post Exposure prophylaxis
Slide 20-

key 20 First line regimens: the principle 2 Nucleosides + 1 Non-nucleoside
Slide 21-

key 21 List of ARVs found in the WHO EDL Nucleoside Reverse Transcriptase Inhibitors abacavir (ABC) didanosine (ddI) lamivudine (3TC) stavudine (d4T) zidovudine (ZDV or AZT)
Slide 22-

key 22 List of ARVs found in the WHO EDL Non - nucleoside Reverse Transcriptase Inhibitors efavirenz (EFV or EFZ) nevirapine (NVP) Protease Inhibitors (PI) indinavir (IDV) lopinavir+ritonavir (LPV/r) nelfinavir (NFV) saquinavir (SQV) ritonavir (booster for IDV, LPV, SQV)
Slide 23-

key 23 .
Slide 24-

key 24 2.3 Considerations that Informed the Choice of First-Line ARV Regimens Potency Side effect profile Maintenance of future options Predicted adherence Availability of fixed dose combinations of antiretrovirals Coexistent medical conditions (TB, and pregnancy or risk thereof) Concomitant medications Presence of resistant viral strain Cost and availability Limited infrastructure Rural delivery
Slide 25-

key 25 2.4 Problems with second-line ARV regimens Multiple resistance mutations High pill burden Limited experience TDF availability ABC hypersensitivity Cold chain for RTV High cost
Slide 26-

key 26 2.5 WHO Recommended First and Second-Line ARV Regimens for HIV Treatment in Adults/Adolescents * NFV in places without cold chain
Slide 27-

key 27 2.6 WHO Recommended First and Second-Line ARV Regimens for Treatment in Children * Insufficient PK data on TDF in children to recommend it as alternative NRTI, and concerns re: bone toxicity of TDF
Slide 28-

key 28 2.7 SIMPLIFIED GUIDELINES FOR ARV TREATMENT (HIV-1 INFECTION) 1st Line Regimen ZDV/3TC + EFV 2nd Line Regimen TDF + ddI + LPV/r If severe CNS symptoms or pregnancy Substitute ZDV to d4T Substitute EFV to NVP If severe anemia Substitute ZDV to ddI (or ABC) If severe anemia and neuropathy or pancreatitis If hepatitis or severe rash Substitute EFV to NFV Therapeutic Failure Substitute LPV/r to NFV (or ATV/r) Substitute TDF to ABC If renal failure If severe dislipidemia If severe GI intolerance Substitute ddI to ABC Substitute LPV/r to SQV/r TB/HIV DISTRICT/REGIONAL LEVEL LOCAL LEVEL
Slide 29-

key 29 Alternative regimens (not in any order of preference) HIV-infected pregnant women without indications for ARV treatment
Slide 30-

key 30 HIV-infected pregnant women with indications for ARV treatment Women Follow the treatment guidelines as for non-pregnant adults except that EFV should not be given in the first trimester First-line regimens: ZDV + 3TC + NVP or d4T + 3TC + NVP Consider delaying initiating ARV treatment until after the first trimester, although for severely ill women the benefits of initiating treatment early clearly outweigh the potential risks Infants ZDV for one week or single-dose NVP or single-dose NVP plus ZDV for one week
Slide 31-

relevant 31 Post-exposure prophylaxis (PEP) Start PEP as soon as possible after exposure to HIV (within 72 H) for a duration of 28 days (4 weeks). Most commonly used for PEP: Bitherapy: AZT + 3 TC (Zidovudine, Lamivudine) (combivir) 300mg AZT+150mg 3TC twice per day for 28 days Triple combination: AZT + 3 TC + IDV Twice per day Combivir and 3 times IDV 800mg per day or other PI such as NFV, LPV/r If drug resistant HIV strain is suspected referral to a specialist is necessary Consider also psychological support, prevention of STIs & unwanted pregnancy Clinical Management of Rape Survivors, WHO & UNHCR, 2004: Revised Edition
Slide 32-

key 32 2.8 Dosages of Antiretroviral Drugs for Adults and Adolescents Drug class/drug Nucleoside RTIs Abacavir (ABC) Didanosine (ddl) Lamivudine (3TC) Stavudine (d4T) Zidovudine (ZDV) Nucleotide RTI Tenofovir (TDF) Dose 300 mg twice daily 400 mg once daily (250 mg once daily if <60 kg) (250 mg once daily if administered with TDF) 150 mg twice daily or 300 mg once daily 40 mg twice daily (30 mg twice daily if <60 kg) 300 mg twice daily 300 mg once daily (Note: drug interaction with ddl necessitates dose reduction of latter)
Slide 33-

key 33 Dosages of Antiretroviral Drugs for Adults and Adolescents Drug class/drug Non-nucleoside RTIs Efavirenz (EFV) Nevirapine (NVP) Protease inhibitors Indinavir/ritonavir (IDV/r) Lopinavir/ritonavir Nelfinavir (NFV) Saquinavir/ritonavir (SQV/r) Dose 600 mg once daily 200 mg once daily for 14 days, then 200 mg twice daily 800 mg/100 mg twice daily 400 mg/100 mg twice daily 533 mg/133 mg twice daily when combined with EFV or NVP) 1250 mg twice daily 1000 mg/100 mg twice daily or 1600 mg/200 mg once daily
Slide 34-

key 34 2.9 Non ARV’s Essential commodities for care of PLWHA Essential HIV and related testing materials and reagents Essential medicines for Opportunistic Infections Medicines for pain relief, palliative care, and mental health problems Condoms Medical supplies: gloves, syringes, needles
Slide 35-

key 35 Conclusion: MAJOR QUESTIONS IN WHO ART GUIDELINES WHEN TO START WHICH ARVs WHO GLOBAL RECOMMENDATIONS REGIONAL AND COUNTRY CRITERIA WHEN TO SUBSTITUTE WHEN TO SWITCH WHEN TO STOP SPECIAL SITUATIONS DRUG FORMULARY 1ST AND 2ND REGIMENS BASIC INFO FOR FORECASTING AND PROCUREMENT
Slide 36-

desirable 36 Major references Scaling up ARV Therapy in resource limited settings: Treatment guidelines for a public Health Approach – WHO, 2003 WHO Model List of Essential Medicines – WHO, March 2005(14th Edition) Clinical Management of Rape Survivors - UNHCR and WHO 2004. Available on CD rom and more information on the AMDS website: http://www.who.int/3by5/amds/en/